Skip to main content

UBS Group AG

Position in RXRX — Recursion Pharmaceuticals, Inc.

CIK 1610520 ZURICH, V8

Position in RXRX

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$32,835,862
+$17,175,067 QoQ
Shares Held
8,947,102
+75.4% QoQ
Ownership
1.67%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#10
of 344 holders
Holding Since
Jun 2021
21 quarters on record
Voting authority Sole 98% Shared 0% None 2%

Common Shares in RXRX Over Time

Shares Held

Position Value (USD)

Derivatives in RXRX

reported options exposure · as of Mar 31, 2026
CallValue
$132,476
CallShares
43,152
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS Group AG holds $8,789,675,806 across 561 Biotechnology names. RXRX ranks #52 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in RXRX

Export CSV
24 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $32,835,862 8,947,102
2026-03-31 $132,476 43,152
2026-03-31 $15,660,795 5,101,237
2025-12-31 $15,100,367 3,692,022
2025-12-31 $176,491 43,152
2025-09-30 $18,318,435 3,753,778
2025-09-30 $917,928 188,100
2025-06-30 $23,430,784 4,630,590
2025-03-31 $29,464,145 5,569,782
2024-12-31 $20,311,398 3,004,645
2024-09-30 $5,271,076 799,860
2024-06-30 $12,367,874 1,649,050
2024-03-31 $6,704,136 672,431
2023-12-31 $6,822,241 691,911
2023-09-30 $2,621,494 342,679
2023-06-30 $1,260,375 168,725
2023-03-31 $1,126,796 168,935
2022-12-31 $2,790,210 361,895
2022-09-30 $196,467 18,465
2022-06-30 $40,586 4,986
2022-03-31 $49,597 6,927
2021-12-31 $4,440,471 259,222
2021-09-30 $1,637,000 71,143
2021-06-30 $25,550 700